Effectiveness of BNT162b2 XBB Vaccine Against XBB and JN.1 Sublineages
Sara Y. Tartof, Jeff Slezak, Laura Puzniak, Timothy B. Frankland, Bradley K. Ackerson, Luis Jódar, John M. McLaughlin
Abstract
We provide updated results (11 October 2023 through 29 February 2024) from our previously conducted test-negative case-control study in Kaiser Permanente Southern California to evaluate sublineage-specific effectiveness of the BNT162b2 XBB1.5-adapted vaccine. Results suggest that XBB1.5-adapted vaccines may have reduced effectiveness against JN.1 versus XBB sublineages.
Topics & Concepts
MedicineSARS-CoV-2 and COVID-19 ResearchViral Infections and Outbreaks ResearchHepatitis B Virus Studies